| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Okt―01 |
Decoding long COVID-associated cardiovascular dysfunction: Mechanisms, models, and new approach methodologies |
Dilip Thomas, Phillip C. Yang, Joseph C. Wu, Nazish Sayed |
| 2 |
[GO] |
2023―Okt―14 |
Profibrotic COVID-19 subphenotype exhibits enhanced localized ER-dependent HSP47+ expression in cardiac myofibroblasts in situ |
Elizabeth R. Jacobs, Gracious R. Ross, Nathan Padilla, Amy Y. Pan, Melodee Liegl, Andrii Puzyrenko, et al. (+10) Shuping Lai, Qiang Dai, Nnamdi Uche, Jason C. Rubenstein, Paula E. North, El-Sayed H. Ibrahim, Yunguang Sun, Juan C. Felix, Hallgeir Rui, Ivor J. Benjamin |
| 3 |
[GO] |
2022―Dez―31 |
Single center experience of CMR findings after COVID-19 and after COVID-19-vaccination |
Patrick Doeblin, Karl Jakob Weiss, Djawid Hashemi, Matthias Schneider, Burkert Pieske, Sebastian Kelle |
| 4 |
[GO] |
2022―Dez―31 |
Development of a mouse model for Sars-Cov-2 studies in the heart |
Javier Duran, Bettina Stolp, Jonas Becker, Matthias Dewenter, Mark Pepin, Ina Ambiel, et al. (+3) Dirk Grimm, Oliver Fackler, Johannes Backs |
| 5 |
[GO] |
2022―Jun―25 |
High frequency of anti-DSG 2 antibodies in post COVID-19 serum samples |
Edward C.Y. Lee, Ryan E. Tyler, Derrick Johnson, Natalie Koh, Ong Biauw Chi, Shi Yin Foo, Jack W.C. Tan |
| 6 |
[GO] |
2022―Mrz―23 |
Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19 |
George R. Abraham, Rhoda E. Kuc, Magnus Althage, Peter J. Greasley, Philip Ambery, Janet J. Maguire, et al. (+4) Ian B. Wilkinson, Stephen P. Hoole, Joseph Cheriyan, Anthony P. Davenport |
| 7 |
[GO] |
2021―Nov―24 |
Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications |
Zhangjing Ma, Kevin Y. Yang, Yu Huang, Kathy O. Lui |
| 8 |
[GO] |
2021―Nov―11 |
Sex- and age-specific regulation of ACE2: Insights into severe COVID-19 susceptibility |
Anissa Viveiros, Mahmoud Gheblawi, Preetinder K. Aujla, Deanna K. Sosnowski, John M. Seubert, Zamaneh Kassiri, Gavin Y. Oudit |
| 9 |
[GO] |
2020―Dez―26 |
Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19 |
Walid Hamouche, Malik Bisserier, Agnieszka Brojakowska, Abrisham Eskandari, Kenneth Fish, David A. Goukassian, Lahouaria Hadri |
| 10 |
[GO] |
2020―Sep―03 |
MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes |
Dongchao Lu, Shambhabi Chatterjee, Ke Xiao, Isabelle Riedel, Yibin Wang, Roger Foo, et al. (+2) Christian Bär, Thomas Thum |
| 11 |
[GO] |
2020―Aug―22 |
Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19 |
Lejla Medzikovic, Christine M. Cunningham, Min Li, Marjan Amjedi, Jason Hong, Gregoire Ruffenach, Mansoureh Eghbali |
| 12 |
[GO] |
2020―Aug―20 |
Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients |
Chenze Li, Jiangang Jiang, Feng Wang, Ning Zhou, Giacomo Veronese, Javid J. Moslehi, et al. (+2) Enrico Ammirati, Dao Wen Wang |
| 13 |
[GO] |
2020―Aug―18 |
Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes |
Emma L. Robinson, Kanar Alkass, Olaf Bergmann, Janet J. Maguire, H. Llewelyn Roderick, Anthony P. Davenport |
| 14 |
[GO] |
2020―Aug―06 |
Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus |
Kirk U. Knowlton |
| 15 |
[GO] |
2020―Jul―18 |
Using “old” medications to fight new COVID-19: Re-purposing with a purpose |
Yibin Wang, Roger Foo, Thomas Thum |
| 16 |
[GO] |
2020―Jul―15 |
Coagulopathy in COVID-19: Focus on vascular thrombotic events |
Wei Shi, Jiagao Lv, Li Lin |
| 17 |
[GO] |
2020―Jun―18 |
Apelin-potential therapy for COVID-19? |
Seyed Soheil Saeedi Saravi, Jürg H. Beer |
| 18 |
[GO] |
2020―Jun―09 |
Cardiac injuries in coronavirus disease 2019 (COVID-19) |
Chen Chen, Huihui Li, Weijian Hang, Dao Wen Wang |
| 19 |
[GO] |
2020―Mai―16 |
p38 MAPK inhibition: A promising therapeutic approach for COVID-19 |
Joseph M. Grimes, Kevin V. Grimes |
| 20 |
[GO] |
2020―Apr―30 |
SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications |
Sonja Groß, Christopher Jahn, Sarah Cushman, Christian Bär, Thomas Thum |
| 21 |
[GO] |
2020―Apr―24 |
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know |
Rahul Dhawan, Rebekah L. Gundry, David M. Brett-Major, Claudius Mahr, Geoffrey M. Thiele, Merry L. Lindsey, Daniel R. Anderson |
| 22 |
[GO] |
2020―Apr―11 |
Cardiovascular molecular mechanisms of disease with COVID-19 |
Roger Foo, Yibin Wang, Wolfram-Hubertus Zimmermann, Johannes Backs, Dao Wen Wang |
| 23 |
[GO] |
2020―Apr―06 |
More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19 |
Shengju Yang, Guoliang Meng |
